Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: A comprehensive narrative overview of English-language studies

International Journal of Drug Policy

Volumn 26, Issue 4, 2015, Pages 352-363

  Fischer, Benedikt ^a,b,c   Blanken, Peter ^d   Da Silveira, Dartiu ^e   Gallassi, Andrea ^f   Goldner, Elliot M ^b   Rehm, Jürgen ^a,c   Tyndall, Mark ^g,h   Wood, Evan ^h,i  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Parnassia Group   (Netherlands)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF BRASILIA   (Brazil)

^g BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Crack cocaine; Dependence; Intervention; Prevention; Review; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMINE DERIVATIVE; METHAMPHETAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; PLACEBO; CENTRAL STIMULANT AGENT; COCAINE;

ABSTINENCE; BEHAVIOR THERAPY; CLINICAL EFFECTIVENESS; COCAINE DEPENDENCE; HEALTH HAZARD; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; PEER COUNSELING; PERSONALIZED MEDICINE; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RISK REDUCTION; SECONDARY PREVENTION; SHORT SURVEY; WITHDRAWAL SYNDROME; ADDICTION; ATTITUDE TO HEALTH; COCAINE-RELATED DISORDERS; DRUG DEPENDENCE TREATMENT; DRUG USE; HEALTH BEHAVIOR; HEALTH CARE DELIVERY; PROCEDURES; PSYCHOLOGY; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME;

BEHAVIOR, ADDICTIVE; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; CRACK COCAINE; DRUG USERS; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; SUBSTANCE ABUSE TREATMENT CENTERS; TREATMENT OUTCOME;

EID: 84926180924     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.01.002     Document Type: Short Survey

References (203)

1. Alvarez Y., Farré M., Fonseca F., Torrens M. Anticonvulsant drugs in cocaine dependence: A systematic review and meta-analysis. Journal of Substance Abuse Treatment 2010, 38(1):66-73.
2. Amato L., Minozzi S., Pani P.P., Solimini R., Vecchi S., Zuccaro P., et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews 2011, 7(12):CD003352.
3. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 2005, 28(4):321-329.
4. Amato L., Minozzi S., Pani P.P., Davoli M. Antipsychotic medications for cocaine dependence. Cochrane Database of Systematic Reviews 2007, (3):CD006306.
5. Amen S.L., Piacentine L.B., Ahmad M.E., Li S.J., Mantsch J.R., Risinger R.C., et al. Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology 2011, 36(4):871-878.
6. Anderson A.L., Vocci F., Ciraulo D., Dackis C., Roache J.D., Salloum I.M., et al. Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence 2009, 104(1-2):133-139.
7. Andrade T., Santiago L., Amari E., Fischer B. 'What a pity!' - Exploring the use of 'pitilho' as harm reduction among crack users in Salvador, Brazil. Drugs: Education, Prevention, Policy 2011, 18(5):382-386.
8. Arria A.M., Wish E.D. Nonmedical use of prescription stimulants among students. Pediatric Annals 2006, 35(8):565-571.
9. Ashcroft R.E., Franey C. Further ethical and social issues in using a cocaine vaccine: Response to hall and carter. Journal of Medical Ethics 2004, 30(4):341-343.
10. Bastos F.I., Bertoni N. Estimativa do número de usuários de crack e/ou similares nas capitais do pais 2013.
11. Baumer E., Lauritsen J., Rosenfeld R., Wright R. The influence of crack cocaine on robbery, burglary and homicide rates: A cross-city longitudinal analysis. Journal of Research in Crime and Delinquency 1998, 35(3):316-340.
12. Bayoumi A.M., Strike C., Brandeau M., Degani N., Fischer B., Glazier R., et al. Report of the Toronto and Ottawa supervised consumption assessment study, 2012 2012, St. Michael's Hospital and the Dalla Lana School of Public Health, University of Toronto, Toronto, ON.
13. Bennett T., Holloway K., Farrington D. The statistical association between drug misuse and crime: A meta-analysis. Aggression and Violent Behavior 2008, 13(2):107-118.
14. Best D., Sidwell C., Gossop M., Harris J., Strang J. Crime and expenditure amongst polydrug misusers seeking treatment: The connection between prescribed methadone and crack use, and criminal involvement. British Journal of Criminology 2001, 41:119-126.
15. Beresford T.P., Clapp L., Martin B., Wiberg J.L., Alfers J., Beresford H.F. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. Journal of Clinical Psychopharmacology 2005, 25(4):363-366.
16. Bisaga A., Aharonovich E., Cheng W.Y., Levin F.R., Mariani J.J., Raby W.N., et al. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug and Alcohol Dependence 2010, 111(1-2):97-104.
17. Boles S., Miotto K. Substance abuse and violence: A review of the literature. Aggression and Violent Behavior 2003, 8(2):155-174.
18. Booth R.E., Kwiatkowski C.F., Chitwood D.D. Sex related HIV risk behaviors: Differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug and Alcohol Dependence 2000, 58(3):219-226.
19. Brodie J.D., Case B.G., Figueroa E., Dewey S.L., Robinson J.A., Wanderling J.A., et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. American Journal of Psychiatry 2009, 166(11):1269-1277.
20. Buchanan D., Tooze J.A., Shaw S., Kinzly M., Heimer R., Singer M. Demographic, HIV risk behavior, and health status characteristics of crack cocaine injectors compared to other injection drug users in three New England cities. Drug and Alcohol Dependence 2006, 81(3):221-229.
21. Bungay V., Johnson J.L., Boyd S.C., Malchy L.A., Buxton J., Loudfoot J. Women's stories/women's lives: Creating safer crack kits. Women's Health and Urban Life 2009, 8(1):28-41.
22. Burkett V.S., Cummins J.M., Dickson R.M., Skolnick M. An open clinical trial utilizing real-time EEG operant conditioning as an adjunctive therapy in the treatment of crack cocaine dependence. Journal of Neurotherapy 2005, 9(2):27-47.
23. Carlini A.E., Galduróz J.C.F., Noto A.R., Nappo S.A. II levantamento domiciliar sobre o uso de drogas psicotrópicas no brasil: Estudo envolvendo as 108 maiores cidades do país: 2005 2006, CEBRID - Centro Brasileiro de Informações Sobre Drogas Psicotrópicas/UNIFESP - Universidade Federal de São Paulo, São Paulo.
24. Carroll K.M., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Archives of General Psychiatry 2004, 61(3):264-272.
25. Castells X., Casas M., Perez-Mana C., Roncero C., Vidal X., Capella D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews 2010, 17(2):CD007380.
26. Ciccarone D. Stimulant abuse: Pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Primary Care 2011, 38(1):41-58.
27. Coffey S.F., Dansky B.S., Carrigan M.H., Brady K.T. Acute and protracted cocaine abstinence in an outpatient population: A prospective study of mood, sleep and withdrawal symptoms. Drug and Alcohol Dependence 2000, 59:277-286.
28. Collins C.L.C., Kerr T., Kuyper L.M., Li K., Tyndall M.W., Marsh D.C., et al. Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use. Journal of Urban Health 2005, 82:276-284.
29. Conners N.A., Bradley R.H., Whiteside-Mansell L., Crone C.C. A comprehensive substance abuse treatment program for women and their children: An initial evaluation. Journal of Substance Abuse Treatment 2001, 21(2):67-75.
30. Conway K.P., Compton W., Stinson F.S., Grant B.F. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the national epidemiologic survey on alcohol and related conditions. Journal of Clinical Psychiatry 2006, 67(2):247-257.
31. Corsi K.F., Rinehart D.J., Kwiatkowski C.F., Booth R.E. Case management outcomes for women who use crack. Journal of Evidence - Based Social Work 2010, 7(1-2):30-40.
32. Cottler L.B., Compton W.M., Ben Abdallah A., Cunningham-Williams R., Abram F., Fichtenbaum C., et al. Peer-delivered interventions reduce HIV risk behaviors among out-of-treatment drug abusers. Public Health Reports 1998, 113(Suppl. 1):31-41.
33. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30(1):205-211.
34. Dackis C.A., O'Brien C.P. Cocaine dependence: A disease of the brain's reward centers. Journal of Substance Abuse Treatment 2001, 21(3):111-117.
35. D'Alberto A. Auricular acupuncture in the treatment of cocaine/crack abuse: A review of the efficacy, the use of the national acupuncture detoxification associational protocol, and the selection of sham points. Journal of Alternative and Complementary Medicine 2004, 10(6):985-1000.
36. DeBeck K., Buxton J., Kerr T., Qi J., Montaner J., Wood E. Public crack cocaine smoking and willingness to use a supervised inhalation facility: Implications for street disorder. Substance Abuse Treatment, Prevention, and Policy 2011, 6:4.
37. DeBeck K., Kerr T., Li K., Fischer B., Buxton J., Montaner J., et al. Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. Canadian Medical Association Journal 2009, 181(9):585-589.
38. Degenhardt L., Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012, 379(9810):55-70.
39. Degenhardt L., Singleton J., Calabria B., McLaren J., Kerr T., Mehta S., et al. Mortality among cocaine users: A systematic review of cohort studies. Drug and Alcohol Dependence 2011, 113(2-3):88-95.
40. Dias A.C., Ribeiro M., Dunn J., Sesso R., Laranjeira R. Follow-up study of crack cocaine users: Situation of the patients after 2, 5, and 12 years. Substance Abuse 2008, 29(3):71-79.
41. Dickson-Gomez J., Bodnar G., Guevara A., Rodriguez K., Gaborit M. Crack use sites and HIV risk in El Salvador. Journal of Drug Issues 2007, 37(2):445-473.
42. Dualibi L.B., Ribeiro M., Laranjeira R. Profile of cocaine and crack users in Brazil. Cadernos De Saúde Pública 2008, 24(Suppl. 4):s545-s557.
43. Dutra L., Stathopoulou G., Basden S.L., Leyro T.M., Powers M.B., Otto M.W. A meta-analytic review of psychosocial interventions for substance use disorders. American Journal of Psychiatry 2008, 165(2):179-187.
44. Edlin B.R., Irwin K.L., Faruque S., McCoy C.B., Word C., Serrano Y., et al. Intersecting epidemics: Crack cocaine use and HIV infection among young inner-city young adults. New England Journal of Medicine 1994, 331(21):1422-1427.
45. Eggertson L. Pfizer advertises smoking cessation drug despite health warnings. Canadian Medical Association Journal 2012, 184(2):127-128.
46. Epele M.E. New toxics, new poverty: A social understanding of the freebase cocaine/paco in Buenos Aires, Argentina. Substance Use & Misuse 2011, 46(12):1468-1476.
47. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Annual report 2007: The state of the drugs problem in Europe 2007, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Available from. http://www.emcdda.europa.eu/publications/annual-report/2007.
48. Falck R.S., Wang J., Carlson R.G. Crack cocaine trajectories among users in a Midwestern American city. Addiction 2007, 102(9):1421-1431.
49. Farronato N.S., Dürsteler-Macfarland K.M., Wiesbeck G.A., Petitjean S.A. A systematic review comparing cognitive-behavioral therapy and contingency management for cocaine dependence. Journal of Addictive Diseases 2013, 32(3):274-287.
50. Faruque S., Edlin B.R., McCoy C.B., Word C.O., Larsen S.A., Schmid D.S., et al. Crack cocaine smoking and oral sores in three inner-city neighborhoods. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996, 13(1):87-92.
51. Fischer B., Monga N., Manzoni P. Differences between co-users of cocaine and crack among Canadian illicit opioid users. Sucht 2005, 51(4):217-224.
52. Fischer B., Coghlan M. Crack in North American cities: The neglected 'epidemic'. Addiction 2007, 102(9):1340-1341.
53. Fischer B., Powis J., Firestone Cruz M., Rudzinski K., Rehm J. Hepatitis C virus transmission among oral crack users: Viral detection on crack paraphernalia. European Journal of Gastroenterology & Hepatology 2008, 20(1):29-32.
54. Fischer B., Rehm J., Patra J., Kalousek K., Haydon E., Tyndall M., et al. Crack across Canada: Comparing crack and non-crack users in a multi-city cohort of opioid and other street drug users. Addiction 2006, 101(12):1760-1770.
55. Ford J.D., Gelernter J., DeVoe J.S., Zhang W., Weiss R.D., Brady K., et al. Association of psychiatric and substance use disorder comorbidity with cocaine dependence severity and treatment utilization in cocaine-dependent individuals. Drug and Alcohol Dependence 2009, 99(1-3):193-203.
56. Freedman M.J., Lester K.M., McNamara C., Milby J.B., Schumacher J.E. Cell phones for ecological momentary assessment with cocaine-addicted homeless patients in treatment. Journal of Substance Abuse Treatment 2006, 30(2):105-111.
57. Glauser J., Queen J.R. An overview of non-cardiac cocaine toxicity. Journal of Emergency Medicine 2007, 32(2):181-186.
58. Gossop M., Marsden J., Stewart D., Kidd T. Changes in use of crack cocaine after drug misuse treatment: 4-5 year follow-up results from the national treatment outcome research study (NTORS). Drug and Alcohol Dependence 2002, 66(1):21-28.
59. Grabowski J., Shearer J., Merrill J., Negus S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviors 2004, 29(7):1439-1464.
60. Greenwald M.K., Ledgerwood D.M., Lundahl L.H., Steinmiller C.L. Effect of experimental analogs of contingency management treatment on cocaine seeking behavior. Drug and Alcohol Dependence 2014, 139:164-168.
61. Greenwald M.K., Lundahl L.H., Steinmiller C.L. Sustained release d-amphetaime reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: A test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers. Neuropsychopharmacology 2010, 35:2624-2637.
62. Grella C.E., Hser Y.I., Hsieh S.C. Predictors of drug treatment re-entry following relapse to cocaine use in DATOS. Journal of Substance Abuse Treatment 2003, 25(3):145-154.
63. Grogger J., Willis M. The emergence of crack cocaine and the rise in urban crime rates. The Review of Economics and Statistics 2000, 82(4):519-529.
64. Haasen C., Prinzleve M., Gossop M., Fischer G., Casas M. Relationship between cocaine use and mental health problems in a sample of European cocaine powder or crack users. World Psychiatry 2005, 4(3):173-176.
65. Hagan H., Pouget E.R., Des Jarlais D.C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Journal of Infectious Diseases 2011, 204(1):74-83.
66. Hall W., Carter L. Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence. Journal of Medical Ethics 2004, 30(4):337-340.
67. Hamilton J.D., Nguyen Q.X., Gerber R.M., Rubio N.B. Olanzapine in cocaine dependence: A double-blind, placebo-controlled trial. American Journal on Addictions 2009, 18(1):48-52.
68. Haney M., Gunderson E.W., Jiang H., Collins E.D., Foltin R.W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biological Psychiatry 2010, 67(1):59-65.
69. Hay G., Gannon M., MacDougall J., Eastwood C., Williams K., Millar T. Opiate and crack cocaine use: A new understanding of prevalence. Drugs: Education, Prevention & Policy 2010, 17(2):135-147.
70. Haydon E., Fischer B. Crack use as a public health problem in Canada - Call for an evaluation of 'safer crack use kits'. Canadian Journal of Public Health 2005, 96(3):185-188.
71. Health Canada Canadian alcohol and drug use monitoring survey (CADUMS): Summary of results for 2012 2014, Available from, (accessed 01.05.14). http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2012/summary-sommaire-eng.php.
72. Hedrich D. European report on drug consumption rooms 2004, European Monitoring Centre on Drugs and Drug Addiction (EMCDDA), Lisbon.
73. Hedrich D., Kerr T., Dubois-Archer F. Drug consumption facilities in Europe and beyond (EMCDDA monographs, harm reduction: Evidence, impacts and challenges) 2010, European Monitoring Centre on Drugs and Drug Addiction (EMCDDA), Lisbon.
74. Henskens R., Garretsen H., Bongers I., Van Dijk A., Sturmans F. Effectiveness of an outreach treatment program for inner city crack abusers: Compliance, outcome, and client satisfaction. Substance Use and Misuse 2008, 43(10):1464-1475.
75. Herin D.V., Rush C.R., Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: Preclinical, human laboratory, and clinical studies. Annals of the New York Academy of Sciences 2010, 1187(1):76-100.
76. Hershberger S.L., Wood M.M., Fisher D.G. A cognitive-behavioral intervention to reduce HIV risk behaviors in crack and injection drug users. AIDS and Behavior 2003, 7(3):229-243.
77. Hicks M.J., Kaminsky S.M., Worgall S., Toth M., Mezey J.G., Crystal R.G., et al. Cocaine analog coupled to disrupted adenovirus: A vaccine strategy to evoke high-titer immunity against addictive drugs. Molecular Therapy 2011, 19(3):612-619.
78. Higgins S.T., Wong C.J., Badger G.J., Ogden D.E., Dantona R.L. Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. Journal of Consulting and Clinical Psychology 2000, 68(1):64-72.
79. Hoffman J.A., Caudill B.D., Koman J.J., Luckey J.W., Flynn P.M., Mayo D.W. Psychosocial treatments for cocaine abuse: 12-month treatment outcomes. Journal of Substance Abuse Treatment 1996, 13(1):3-11.
80. Hoffman J.A., Klein H., Clark D.C., Boyd F.T. The effect of entering drug treatment on involvement in HIV-related risk behaviors. American Journal of Drug & Alcohol Abuse 1998, 24(2):259-284.
81. Hope V.D., Hickman M., Tilling K. Capturing crack cocaine use: Estimating the prevalence of crack cocaine use in London using capture-recapture with covariates. Addiction (Abingdon, England) 2005, 100(11):1701-1708.
82. Howard A.A., Klein R.S., Schoenbaum E.E., Gourevitch M.N. Crack cocaine use and other risk factors for tuberculin positivity in drug users. Clinical Infectious Diseases 2002, 35(10):1183-1190.
83. Hunt N. The evaluation of literature on drug consumption rooms (paper B): The report of the independent working group on drug consumption rooms 2006, The Joseph Rowntree Foundation, York, UK.
84. Hunt N. An overview of models of delivery of drug consumption rooms (paper C). The report of the independent working group on drug consumption rooms 2006, Joseph Rowntree Foundation, York, UK.
85. Ilse J., Prinzleve M., Zurhold H., Haasan C. Cocaine and crack use and dependence in Europe - Experts view on an increasing public health problem. Addiction Research and Theory 2006, 14(5):437-452.
86. Ingersoll K.S., Farrell-Carnahan L., Cohen-Filipic J., Heckman C.J., Ceperich S.D., Hettema J., et al. A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack cocaine users. Drug and Alcohol Dependence 2011, 116(1-3):177-187.
87. Ivsins A., Roth E., Nakamura N., Krajden M., Fischer B. Uptake, benefits of and barriers to safer crack use kit (SCUK) distribution programmes in Victoria, Canada - A qualitative exploration. International Journal of Drug Policy 2011, 22(4):292-300.
88. Kampman K.M. What's new in the treatment of cocaine addiction?. Current Psychiatry Reports 2010, 12(5):441-447.
89. Kampman K.M., Pettinati H., Lynch K.G., Dackis C., Sparkman T., Weigley C., et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug and Alcohol Dependence 2004, 75(3):233-240.
90. Kampman K.M., Pettinati H., Lynch K.G., Sparkman T., O'Brien C.P. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug and Alcohol Dependence 2003, 70(3):265-273.
91. Karila L., Gorelick D., Weinstein A., Noble F., Benyamina A., Coscas S., et al. New treatments for cocaine dependence: A focused review. International Journal of Neuropsychopharmacology 2008, 11(3):425-438.
92. Karila L., Reynaud M., Aubin H.J., Rolland B., Guardia D., Cottencin O., et al. Pharmacological treatments for cocaine dependence: Is there something new?. Current Pharmaceutical Design 2011, 17(14):1359-1368.
93. Kessler R.C., Chiu W.T., Demier O., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry 2005, 62(6):617-627.
94. Khan M.R., Berger A., Hemberg J., O'Neill A., Penniman Dyer T., Smyrk K. Non-injection and injection drug use and STI/HIV risks in the united states: The degree to which sexual risk behaviors versus sex with an STI-infected partner account for infection transmission among drug users. AIDS and Behavior 2013, 17(3):1185-1194.
95. Kimber J., Dolan K., Wodak A. Survey of drug consumption rooms: Service delivery and perceived public health and amenity impact. Drug and Alcohol Review 2005, 24(1):21-24.
96. Kirby K.C., Marlowe D.B., Festinger D.S., Lamb R.J., Platt J.J. Schedule of voucher delivery influences initiation of cocaine abstinence. Journal of Consulting and Clinical Psychology 1998, 66(5):761-767.
97. Kloner R.A., Hale S., Alker K., Rezkalla S. Effects of acute and chronic cocaine use on the heart. Circulation 1992, 85(2):407-419.
98. Knapp W.P., Soares B.G.O., Farrell M., Lima M.S. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorder. Cochrane Database of Systematic Reviews 2007, 18(3):CD003023.
99. Kosten T.R., Rosen M., Bond J., Settles M., Roberts J.S.C., Shields J., et al. Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine 2002, 20(7-8):1196-1204.
100. Kothner U., Langer F., Klee J. Drug consumption rooms in Germany: A situational assessment by the AK Konsumraum 2011, Deutsch AIDS-Hilfe and the Federal Association for Accepting Drug Work and Human Drug Policy, Berlin, Germany.
101. Labigalini E., Rodrigues L.R., Da Silveira D.X. Therapeutic use of cannabis by crack addicts in Brazil. Journal of Psychoactive Drugs 1999, 31(4):451-455.
102. Lanehart R.E., Clark H.B. Case management of pregnant and parenting female crack and polydrug abusers. Journal of Substance Abuse 1994, 6(4):441-448.
103. LaRowe S.D., Kalivas P.W., Nicholas J.S., Randall P.K., Mardikian P.N., Malcolm R.J. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. American Journal on Addictions 2013, 22(5):443-452.
104. LaRowe S.D., Myrick H., Hedden S., Mardikian P., Saladin M., McRae A., et al. Is cocaine desire reduced by N-acetylcysteine?. American Journal of Psychiatry 2007, 164(7):1115-1117.
105. Latka M.H., Wilson T.E., Cook J.A., Bacon M.C., Richardson J.L., Sohler N., et al. Impact of drug treatment on subsequent sexual risk behavior in a multisite cohort of drug-using women: A report from the women's interagency HIV study. Journal of Substance Abuse Treatment 2005, 29(4):329-337.
106. Lee N.K., Rawson R.A. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug and Alcohol Review 2008, 27(3):309-317.
107. Lejuez C.W., Zvolensky M.J., Daughters S.B., Bornovalova M.A., Paulson A., Tull M.T., et al. Anxiety sensitivity: A unique predictor of dropout among inner-city heroin and crack/cocaine users in residential substance use treatment. Behaviour Research and Therapy 2008, 46(7):811-818.
108. Leonard L., DeRubeis E., Pelude L., Medd E., Birkett N., Seto J. I inject less as I have easier access to pipes injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. International Journal of Drug Policy 2008, 19(3):255-264.
109. Levin F.R., Evans S.M., Brooks D.J., Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug and Alcohol Dependence 2007, 87(1):20-29.
110. Loebl T., Angarita G.A., Pachas G.N., Huang K.L., Lee S.H., Nino J., et al. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. Journal of Clinical Psychiatry 2008, 69(3):480-486.
111. Lussier J.P., Heil S.H., Mongeon J.A., Badger G.J., Higgins S.T. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006, 101(2):192-203.
112. MacArthur G.J., Minozzi S., Martin N., Vickerman P., Deren S., Bruneau J., et al. Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. BMJ (Clinical Research Ed.) 2012, 345:e5945.
113. Malchy L.A., Bungay V., Johnson J.L., Buxton J. Do crack smoking practices change with the introduction of safer crack kits?. Canadian Journal of Public Health 2011, 102(3):188-192.
114. Malchy L.A., Bungay V., Johnson J. Documenting practices and perceptions of 'safer' crack use: A Canadian pilot study. International Journal of Drug Policy 2008, 19(4):339-341.
115. Malcolm R., Olive M.F., Lechner W. The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: Guidance for clinical practice. Expert Opinion on Drug Safety 2008, 7(4):459-472.
116. Mardikian P.N., LaRowe S.D., Hedden S., Kalivas P.W., Malcolm R.J. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study. Progress in Neuropsychopharmacology & Biological Psychiatry 2007, 31(2):389-394.
117. Marlowe D.B., Kirby K.C., Festinger D.S., Merikle E.P., Tran G.Q., Platt J.J. Day treatment for cocaine dependence: Incremental utility over outpatient counseling and voucher incentives. Addictive Behaviors 2003, 28(2):387-398.
118. Marsden J., Eastwood B., Bradbury C., Dale-Perera A., Farrell M., Hammond P., et al. Effectiveness of community treatments for heroin and crack cocaine addiction in England: A prospective, in-treatment cohort study. Lancet 2009, 374(9697):1262-1270.
119. Martell B.A., Mitchell E., Poling J., Gonsai K., Kosten T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry 2005, 58(2):158-164.
120. Martell B.A., Orson F.M., Poling J., Mitchell E., Rossen R.D., Gardner T., et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: A randomized, double-blind, placebo-controlled efficacy trial. Archives of General Psychiatry 2009, 66(10):1116-1123.
121. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, 3. CD002209.
122. Maude-Griffin P.M., Hohenstein J.M., Humfleet G.L., Reilly P.M., Tusel D.J., Hall S.M. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: Main and matching effects. Journal of Consulting and Clinical Psychology 1998, 66(5):832-837.
123. McCoy H.V., McCoy C.B., Lai S., Weatherby N.L., Messiah S. Behavior changes among crack-using rural and urban women. Substance Use & Misuse 1999, 34(4-5):667-684.
124. Meini M., Rucci P., Moncini M., Cecconi D., Cellesi V., Biasci L., et al. Safety, tolerability, and self-rated effects of aripiprazole and ropinirole treatment for cocaine dependence: A pilot study. American Journal on Addictions 2011, 20(2):179-180.
125. Milby J.B., Schumacher J.E., McNamara C., Wallace D., Usdan S., McGill T., et al. Initiating abstinence in cocaine abusing dually diagnosed homeless persons. Drug and Alcohol Dependence 2000, 60(1):55-67.
126. Milby J.B., Schumacher J.E., Raczynski J.M., Caldwell E., Engle M., Michael M., et al. Sufficient conditions for effective treatment of substance abusing homeless persons. Drug and Alcohol Dependence 1996, 43(1-2):39-47.
127. Milby J.B., Schumacher J.E., Vuchinich R.E., Freedman M.J., Kertesz S., Wallace D. Toward cost-effective initial care for substance-abusing homeless. Journal of Substance Abuse Treatment 2008, 34(2):180-191.
128. Milby J.B., Schumacher J.E., Wallace D., Freedman M.J., Vuchinich R.E. To house or not to house: The effects of providing housing to homeless substance abusers in treatment. American Journal of Public Health 2005, 95(7):1259-1265.
129. Milby J.B., Schumacher J.E., Wallace D., Frison S., McNamara C., Usdan S., et al. Day treatment with contingency management for cocaine abuse in homeless persons: 12-month follow-up. Journal of Consulting and Clinical Psychology 2003, 71(3):619-621.
130. Minozzi S., Amato L., Davoli M., Farrell M., Lima Reisser A.A., Pani P.P., et al. Anticonvulsants for cocaine dependence. Cochrane Database of Systematic Reviews 2008, 16(2):CD006754.
131. Mooney M.E., Herin D.V., Schmitz J.M., Moukaddam N., Green C.E., Grabowski J. Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence 2009, 101(1-2):34-41.
132. Nuijten M., Blanken P., van den Brink W., Hendriks V. Cocaine addiction treatments to improve control and reduce harm (CATCH): New pharmacological treatment options for crack-cocaine dependence in the Netherlands. BMC Psychiatry 2011, 11:135.
133. Nuijten M., Blanken P., van den Brink W., Hendriks V. Treatment of crack-cocaine dependence with topiramate: A randomized controlled feasibility trial in the Netherlands. Drug and Alcohol Dependence 2014, 138:177-184.
134. Nyamathi A.M., Dixon E.L., Robbins W., Smith C., Wiley D., Leake B., et al. Risk factors for hepatitis C virus infection among homeless adults. Journal of General Internal Medicine 2002, 17(2):134-143.
135. O'Driscoll P.T., McGough J., Hagan H., Thiede H., Critchlow C., Alexander E.R. Predictors of accidental fatal drug overdose among a cohort of injection drug users. American Journal of Public Health 2001, 91(6):984-987.
136. Oliveira L.G., Ponce J.C., Nappo S.A. Crack cocaine use in Barcelona: A reason of worry. Substance Use & Misuse 2010, 45(13):2291-2300.
137. Oliveto A., Chopra M.P., Gonzalez-Haddad G., Carroll K.M., Kosten T.R., Poling J., et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug and Alcohol Dependence 2011, 113(2-3):184-191.
138. Pani P.P., Trogu E., Vecchi S., Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database of Systematic Reviews 2011, 12(7):12-2950.
139. Pérez A.O., Cruyff M., Benschop A., Korf D.J. Estimating the prevalence of crack dependence using capture-recapture with institutional and field data: A three-city study in the Netherlands. Substance Use & Misuse 2013, 48(1-2):173-180.
140. Pettinati H.M., Kampman K.M., Lynch K.G., Xie H., Dackis C., Rabinowitz A.R., et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors 2008, 33(5):651-667.
141. Plebani J.G., Lynch K.G., Yu Q., Pettinati H.M., O'Brien C.P., Kampman K.M. Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug and Alcohol Dependence 2012, 121(1-2):163-166.
142. Poling J., Oliveto A., Petry N., Sofuoglu M., Gonsai K., Gonzalez G., et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Archives of General Psychiatry 2006, 63(2):219-228.
143. Poling J., Rounsaville B., Gonsai K., Severino K., Sofuoglu M. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: A pilot study. American Journal on Addictions 2010, 19(5):401-408.
144. Porter J., Bonilla L., Drucker E. Methods of smoking crack as a potential risk factor for HIV infection: Crack smokers' perceptions and behavior. Contemporary Drug Problems 1997, 24(2):219-347.
145. Prendergast M., Podus D., Finney J., Greenwell L., Roll J. Contingency management for treatment of substance use disorders: A meta-analysis. Addiction 2006, 101(11):1546-1560.
146. Prinzleve M., Haasen C., Zurhold H., Matali J., Bruguera E., Gerevich J., et al. Cocaine use in Europe - A multi-centre study: Patterns of use in different groups. European Addiction Research 2004, 10:147-156.
147. Prudhomme-White B.P., Becker-Blease K.A., Grace-Bishop K. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. Journal of American College Health 2006, 54(5):261-268.
148. Reis A.D., Castro L.A., Faria R., Laranjeira R. Craving decrease with topiramate in outpatient treatment for cocaine dependence: An open label trial. Revista Brasileira De Psiquiatria 2008, 30(2):132-135.
149. Ribeiro M., Dunn J., Sesso R., Dias A.C., Laranjeira R. Causes of death among crack cocaine users. Revista Brasileira De Psiquiatria 2006, 28(3):196-202.
150. Ribeiro M., Dunn J., Laranjeira R., Sesso R. High mortality among young crack cocaine users in Brazil: A 5-year follow-up study. Addiction 2004, 99(9):1133-1135.
151. Richard A.J., Montoya I.D., Nelson R., Spence R.T. Effectiveness of adjunct therapies in crack cocaine treatment. Journal of Substance Abuse Treatment 1995, 12(6):401-413.
152. Ritter A., Cameron J. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug and Alcohol Review 2006, 25(6):611-624.
153. Roll J.M., Chermack S.T., Chudzynski J.E. Investigating the use of contingency management in the treatment of cocaine abuse among individuals with schizophrenia: A feasibility study. Psychiatry Research 2004, 125(1):61-64.
154. Ross M.W., Timpson S.C., Williams M.L., Bowen A. The impact of HIV-related interventions on HIV risk behavior in a community sample of African American crack cocaine users. AIDS Care 2007, 19(5):608-616.
155. Rotheram-Borus M.J., Rhodes F., Desmond K., Weiss R.E. Reducing HIV risks among active injection drug and crack users: The safety counts program. AIDS and Behavior 2010, 14(3):658-668.
156. Rush C.R., Stoops W.W., Hays L.R. Cocaine effects during d-amphetamine maintenance: A human laboratory analysis of safety, tolerability and efficacy. Drug and Alcohol Dependence 2009, 99(1-3):261-271.
157. Santibanez S.S., Garfein R.S., Swatzendruber A., Kerndt P.R., Morse E., Ompad D., et al. Prevalence and correlates of crack-cocaine injection among young injection drug users in the United States, 1997-1998. Drug and Alcohol Dependence 2005, 77(3):227-233.
158. Santos Cruz M., Andrade T., Bastos F., Leal E., Bertoni N., Lipman L., et al. Patterns, determinants and barriers of health and social service utilization among young urban crack users in Brazil. BMC Health Services Research 2013, 13:536.
159. Santos Cruz M., Andrade T., Bastos F.I., Leal E., Bertoni N., Melo-Villar L., et al. 1001 Key drug use, health and socio-economic characteristics of young crack users in two Brazilian cities. International Journal of Drug Policy 2013, 24(5):432-438.
160. Schatz E., Nougier M. Drug consumption rooms: Evidence and practice (international drug policy consortium (IDPC) briefing paper) 2012, International Drug Policy Consortium (IDPC), London, UK.
161. Schlosser A.V., Abdallah A.B., Callahan C.L., Bradford S., Cottler L.B. Does readiness to change predict reduced crack use in human immunodeficiency virus prevention?. Journal of Substance Abuse Treatment 2008, 35(1):28-35.
162. Schottenfeld R.S., Moore B., Pantalon M.V. Contingency management with community reinforcement approach or twelve-step facilitation drug counseling for cocaine dependent pregnant women or women with young children. Drug and Alcohol Dependence 2011, 118(1):48-55.
163. Schubiner H., Saules K.K., Arfken C.L., Johanson C.E., Schuster C.R., Lockhart N., et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology 2002, 10(3):286-294.
164. Schumacher J.E., Milby J.B., Wallace D., Meehan D.C., Kertesz S., Vuchinich R., et al. Meta-analysis of day treatment and contingency-management dismantling research: Birmingham homeless cocaine studies (1990-2006). Journal of Consulting and Clinical Psychology 2007, 75(5):823-828.
165. Schumacher J.E., Milby J.B., Wallace D., Simpson C., Frison S., McNamara C., et al. Diagnostic compared with abstinence outcomes of day treatment and contingency management among cocaine-dependent homeless persons. Experimental and Clinical Psychopharmacology 2003, 11(2):146-157.
166. Schumacher J.E., Usdan S., Milby J.B., Wallace D., McNamara C. Abstinent-contingent housing and treatment retention among crack-cocaine-dependent homeless persons. Journal of Substance Abuse Treatment 2000, 19(1):81-88.
167. Scott W.C., Kaiser D., Othmer S., Sideroff S.I. Effects of an EEG biofeedback protocol on a mixed substance abusing population. American Journal of Drug and Alcohol Abuse 2005, 31(3):455-469.
168. Shannon K., Ishida T., Morgan R., Bear A., Oleson M., Kerr T., et al. Potential community and public health impacts of medically supervised safer smoking facilities for crack cocaine users. Harm Reduction Journal 2006, 3:1.
169. Shearer J. The principles of agonist pharmacotherapy for psychostimulant dependence. Drug and Alcohol Review 2008, 27(3):301-308.
170. Shearer J., Wodak A., van Beek I., Mattick R.P., Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction (Abingdon, England) 2003, 98(8):1137-1141.
171. Shoptaw S., Heinzerling K.G., Rotheram-Fuller E., Kao U.H., Wang P.C., Bholat M.A., et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. Journal of Addictive Diseases 2008, 27(1):13-23.
172. Shoptaw S., Yang X.W., Rotheram-Fuller E.J., Hsieh Y.C.M., Kintaudi P.C., Charuvastra V.C., et al. Randomized placebo-controlled trial of Baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. Journal of Clinical Psychiatry 2003, 64(12):1440-1448.
173. Shorter D., Kosten T.R. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Medicine 2011, 9:119-127.
174. Siegal H.A., Li L., Rapp R.C. Abstinence trajectories among treated crack cocaine users. Addictive Behaviors 2002, 27(3):437-449.
175. Silverman K., Svikis D., Robles E., Stitzer M.L., Bigelow G.E. A reinforcement-based therapeutic workplace for the treatment of drug abuse: Six-month abstinence outcomes. Experimental and Clinical Psychopharmacology 2001, 9(1):14-23.
176. Somaini L., Donnini C., Raggi M.A., Amore M., Ciccocioppo R., Saracino M.A., et al. Promising medications for cocaine dependence treatment. Recent Patents on CNS Drug Discovery 2011, 6(2):146-160.
177. Somoza E.C., Wulsin L.R., Barrett J.A., Winhusen T.M., Bridge T.P., Rotrosen J.P., et al. An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. Journal of Addictive Diseases 2004, 23(1):77-92.
178. Sterk C.E., Klein H., Elifson K.W. Perceived condom use self-efficacy among at-risk women. AIDS and Behavior 2003, 7(2):175-182.
179. Sterk C.E., Theall K.P., Elifson K.W. Effectiveness of a risk reduction intervention among African American women who use crack cocaine. AIDS Education and Prevention 2003, 15(1):15-32.
180. Stoever H. Crack cocaine in Germany - current state of affairs. Journal of Drug Issues 2002, 32(2):413-421.
181. Strathdee S.A., Navarro J.R. Commentary on salmon et al. (2010): The case for safer inhalation facilities - Waiting to inhale. Addiction 2010, 105(4):684-685.
182. Strathdee S.A., Stockman J.K. Epidemiology of HIV among injecting and non-injecting drug users: Current trends and implications for interventions. Current HIV/AIDS Reports 2010, 7(2):99-106.
183. Strathdee S.A., Vlahov D. The effectiveness of needle exchange programs: A review of the science and policy. AID Science 2001, 1(16).
184. Substance Abuse and Mental Health Services Administration (SAMHSA) Results from the 2012 national survey on drug use and health: Summary of national findings No. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD.
185. Ti L., Buxton J., Wood E., Shannon K., Zhang R., Montaner J., et al. Factors associated with difficulty accessing crack cocaine pipes in a Canadian setting. Drug and Alcohol Review 2012, 31(7):890-896.
186. Torchalla I., Strehlau V., Li K., Krausz M. Substance use and predictors of substance dependence in homeless women. Drug and Alcohol Dependence 2011, 118(2-3):173-179.
187. Tortu S., Neaigus A., McMahon J., Hagen D. Hepatitis C among noninjecting drug users: A report. Substance Use & Misuse 2001, 36(4):523-534.
188. United Nations Office on Drugs and Crime (UNODC) World drug report, 2012 2012, United Nations Office on Drugs and Crime (UNODC), Vienna, Austria.
189. United Nations Office on Drugs and Crime (UNODC) World drug report 2014 No. E.14.XI.7 2014, United Nations Publication, Vienna.
190. Vandrey R., Bigelow G.E., Stitzer M.L. Contingency management in cocaine abusers: A dose-effect comparison of goods-based versus cash-based incentives. Experimental and Clinical Psychopharmacology 2007, 15(4):338-343.
191. Volkow N.D., Fowler J.S., Wang G.J., Goldstein R.Z. Role of dopamine, the frontal cortex and memory circuits in drug addiction: Insight from imaging studies. Neurobiology of Learning and Memory 2002, 78(3):610-624.
192. Vorspan F., Bellais L., Keijzer L., Lépine J.P. An open-label study of aripiprazole in nonschizophrenic crack-dependent patients. Journal of Clinical Psychopharmacology 2008, 28(5):570-572.
193. Wechsberg W.M., Novak S.P., Zule W.A., Browne F.A., Kral A.H., Ellerson R.M., et al. Sustainability of intervention effects of an evidence-based HIV prevention intervention for African American women who smoke crack cocaine. Drug and Alcohol Dependence 2010, 109(1-3):205-212.
194. Wechsberg W.M., Lam W.K.K., Zule W.A., Bobashev G. Efficacy of a woman-focused intervention to reduce HIV risk and increase self-sufficiency among African American crack abusers. American Journal of Public Health 2004, 94(7):1165-1173.
195. Wee S., Hicks M.J., De B.P., Rosenberg J.B., Moreno A.Y., Kaminsky S.M., et al. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology 2012, 37(5):1083-1091.
196. Weeks M.R., Li J., Dickson-Gomez J., Convey M., Martinez M., Radda K., et al. Outcomes of a peer HIV prevention program with injection drug and crack users: The risk avoidance partnership. Substance Use & Misuse 2009, 44(2):253-281.
197. Werb D., DeBeck K., Kerr T., Li K., Montaner J., Wood E. Modelling crack cocaine use trends over 10 years in a Canadian setting. Drug and Alcohol Review 2010, 29(3):271-277.
198. Williams M., Bowen A., Atkinson J.S., Nilsson-Schonnesson L., Diamond P.M., Ross M.W., et al. An assessment of brief group interventions to increase condom use by heterosexual crack smokers living with HIV infection. AIDS Care 2012, 24(2):220-231.
199. Winhusen T., Osman S., Mezinskis J., Li S.H., Lewis D., Horn P., et al. A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug and Alcohol Dependence 2007, 91(2-3):141-148.
200. Wood E., Kerr T., Tyndall M., Montaner J. The Canadian government's treatment of scientific process and evidence: Inside the evaluation of North America's first medically supervised safer injection facility. International Journal of Drug Policy 2008, 19:220-225.
201. Wood E., McKinnon M., Strang R., Kendall P.R. Improving community health and safety in Canada through evidence-based policies on illegal drugs. Open Medicine 2012, 6(1):e35-e40.
202. Young M.J., Sisti D.A., Rimon-Greenspan H., Schwartz J.L., Caplan A.L. Immune to addiction: The ethical dimensions of vaccines against substance abuse. Nature Immunology 2012, 13(6):521-524.
203. Zobel F., Dubois-Arber F. Short appraisal on the role and usefulness of drug consumption facilities (DCF) in the reduction of drug-related problems in Switzerland 2004, University Institute of Social and Preventive Medicine, Lausanne. Switzerland.